Study Title

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Study Details

Description:

This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.

Sponsor:

MD Anderson Cancer Center

Government Study Link:

NCT06549413 - Click here to see study on

ClinicalTrials.gov

Drug Details

18F-FSPG
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • Cystine/glutamate antiporter

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468